

**PROTOCOL CODE: ULYOGLOFIT**  
**Cycles 2 to 12**

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment.

<b>DOCTOR'S ORDERS</b>			Ht _____ cm	Wt _____ kg	BSA _____ m <sup>2</sup>
<b>REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy &amp; Alert Form</b>					
<b>DATE:</b>	<b>To be given:</b>	<b>Cycle #:</b>			
Date of Previous Cycle: _____					
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> <b>CBC &amp; Diff</b> of treatment May proceed with doses as written if within 48 hours <b>ANC greater than or equal to 0.5 x 10<sup>9</sup>/L, platelets greater than or equal to 50 x 10<sup>9</sup>/L</b> Dose modification for: <input type="checkbox"/> Other Toxicity: _____ Proceed with treatment based on blood work from _____					
<b>PREMEDICATIONS:</b> Patient to take own supply. RN/Pharmacist to confirm _____. <ul style="list-style-type: none"> <li>• Physician to ensure antiviral and antimicrobial prophylaxis, if applicable</li> </ul> <p>Cycles 2 and 3:          60 minutes prior to treatment: <b>dexamethasone 20 mg IV</b>          30 minutes prior to treatment: <b>acetaminophen 650 to 975 mg PO</b> and <b>diphenhydrAMINE 50 mg</b> <input type="checkbox"/> PO or <input type="checkbox"/> IV (select one)</p> <p>Cycles 4 to 12:          Optional if CRS with previous dose:  <input type="checkbox"/> 60 minutes prior to treatment: <b>dexamethasone 20 mg IV</b>          30 minutes prior to treatment: <b>acetaminophen 650 to 975 mg PO</b> and <b>diphenhydrAMINE 50 mg</b> <input type="checkbox"/> PO or <input type="checkbox"/> IV (select one)  <input type="checkbox"/> <b>Other:</b> _____</p>					
<b>MONITORING:</b>  If Grade 2 or higher CRS with previous dose, inpatient treatment required. Patients to be monitored during infusion and for at least 24 hours after infusion completed. See protocol for details.  <b>Cytokine release syndrome (CRS)</b> Patients should be closely monitored for early signs and symptoms indicative of CRS – in particular fever (temperature greater than 38 degrees Celsius), chills, hypoxia, hypotension (systolic blood pressure less than 100 mmHg or drop of greater than 20 mmHg from baseline), dyspnea, and tachycardia. Refer to protocol and to the separate <u>SCCRS PPO</u> for specific management of CRS.					
<b>ADDITIONAL ORDERS IF INPATIENT TREATMENT:</b>  <b>valACYclovir 500 mg PO</b> once daily <b>cotrimoxazole 1 DS tablet PO</b> 3 times each week (Monday, Wednesday and Friday)					
<b>PREHYDRATION:</b> <input type="checkbox"/> 500 mL NS IV over 30 minutes prior to glofitamab					
<b>DOCTOR'S SIGNATURE:</b>					<b>SIGNATURE:</b>
					<b>UC:</b>

**PROTOCOL CODE: ULYOGLOFIT**  
**Cycles 2 to 12**

<b>DATE:</b>	
<b>** Have Hypersensitivity Reaction Tray and Protocol Available**</b>	
<b>TREATMENT:</b>	
<input type="checkbox"/> <b>Cycle 2:</b> <input type="checkbox"/> If no Grade 2 or higher CRS with previous dose: <b>ambulatory care treatment</b> Vital signs prior to glofitamab, at the end of the infusion, and as clinically indicated. <b>glofitamab 30 mg IV in 100 mL NS over 4 hours</b>	
<b>OR</b>	
<input type="checkbox"/> If Grade 2 or higher CRS with previous dose: <b>inpatient treatment</b> In addition to IV for treatment, insert saline lock for emergency management. Vital signs prior to glofitamab, every hour during infusion, at the end of the infusion, and as clinically indicated. <b>glofitamab 30 mg IV in 100 mL NS over 8 hours</b> Concurrent infusion with glofitamab: Infuse NS IV at 20 mL/h via Y-site connector placed immediately before the injection site	
<input type="checkbox"/> <b>Cycles 3 to 12:</b> <input type="checkbox"/> If no Grade 2 or higher CRS with previous dose: <b>ambulatory care treatment</b> Vital signs prior to glofitamab, at the end of the infusion, and as clinically indicated. <b>glofitamab 30 mg IV in 100 mL NS over 2 hours</b>	
<b>OR</b>	
<input type="checkbox"/> If Grade 2 or higher CRS with previous dose: <b>inpatient treatment</b> In addition to IV for treatment, insert saline lock for emergency management. Vital signs prior to glofitamab, every hour during infusion, at the end of the infusion, and as clinically indicated. <b>glofitamab 30 mg IV in 100 mL NS over 4 hours</b>	
<b>RETURN APPOINTMENT ORDERS</b>	
<input type="checkbox"/> Return in <b>three</b> weeks for Doctor and Cycle _____. Book treatment on Day 1. <input type="checkbox"/> Return in <b>three</b> weeks for Doctor and Cycle _____. Admit to hospital for Cycle _____ <input type="checkbox"/> Last cycle. Return in _____ week(s).	
<b>CBC &amp; Diff</b> prior to each cycle If clinically indicated: <input type="checkbox"/> creatinine <input type="checkbox"/> sodium <input type="checkbox"/> potassium <input type="checkbox"/> phosphate <input type="checkbox"/> calcium <input type="checkbox"/> magnesium <input type="checkbox"/> uric acid <input type="checkbox"/> albumin <input type="checkbox"/> total bilirubin <input type="checkbox"/> ALT <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> GGT <input type="checkbox"/> LDH <input type="checkbox"/> random glucose <input type="checkbox"/> immunoglobulin panel (IgA, IgG, IgM) <input type="checkbox"/> HBV viral load every 3 months <input type="checkbox"/> Other tests: <input type="checkbox"/> Consults: <input type="checkbox"/> See general orders sheet for additional requests.	
<b>DOCTOR'S SIGNATURE:</b>	<b>SIGNATURE:</b>
	<b>UC:</b>